+------------------------------------------------------------------------------+
BN 11/11 07:03 *SHIRE SAYS PURCHASE EXPANDS RARE DISEASE PORTFOLIO
BN 11/11 07:03 *SHIRE SEES VIROPHARMA EXCELLENT STRATEGIC FIT
BN 11/11 07:02 *SHIRE PURCHASE OF VIROPHARMA VALUED AT ABOUT $4.2 BLN
BFW 11/11 07:02 *SHIRE TO BUY VIROPHARMA FOR TOTAL CONSIDERATION OF AROUND $4.2B
BN 11/11 07:02 *SHIRE TO PURCHASE VIROPHARMA FOR $50/SHARE IN CASH
BN 11/11 07:01 *SHIRE TO PURCHASE VIROPHARMA FOR $50/SHARE IN CASH
BN 11/11 07:01 *SHIRE EARNINGS ADDING REV GROWTH-ENHANCING PURCHASE
BN 11/11 07:00 *SHIRE SHIRE TO BUY VIROPHARMA
+------------------------------------------------------------------------------+
SHIRE PLC: Shire to acquire ViroPharma
2013-11-11 07:00:23.423 GMT
Shire to acquire ViroPharma in strategic move to strengthen rare disease
portfolio; will augment already strong growth prospects
Earnings accretive, revenue growth-enhancing acquisition
Dublin, Ireland and Exton, PA, US - November 11, 2013 - Shire plc (LSE: SHP,
NASDAQ: SHPG) and ViroPharma Incorporated (NASDAQ: VPHM) today announce that
their Boards of Directors have unanimously approved, and the companies have
entered into, a merger agreement pursuant to which Shire will acquire all the
outstanding shares of the rare disease company ViroPharma for $50 per share in
cash, for a total consideration of approximately $4.2 billion. The $50 per
share price in the transaction represents a 27% premium to ViroPharma's closing
share price on Friday, November 8, 2013, the last trading day prior to
announcement, and a 64% premium to ViroPharma's unaffected share price of
$30.47 on September 12, 2013.
ViroPharma is a high growth, rare disease biopharmaceutical company, whose
commercial product CINRYZE® (C1 esterase inhibitor [human]), is a leading
brand
for the prophylactic treatment of Hereditary Angioedema (HAE).
Shire transaction highlights
* Excellent strategic fit
* Expands rare disease portfolio which Shire is strategically committed to
strengthen
* Adds CINRYZE, with growing sales in the prophylactic treatment of HAE,
which complements Shire's FIRAZYR®(icatibant injection)
* Enhances Shire's short and long term revenue growth profile
* Expected annual cost synergies of approximately $150 million by 2015, over
and above the improved operating leverage already being driven by the
ongoing One Shire reorganization
* Immediately accretive to Shire's Non GAAP EPS following completion and
enhances earnings growth profile
* Shire expects transaction to deliver ROIC in excess of its weighted average
cost of capital
* Acquisition to be effected by a tender offer and funded from Shire's cash
resources and existing and new bank facilities
* Conference call for investors today (details below)
Shire Chief Executive Officer, Flemming Ornskov MD comments:
"The acquisition of ViroPharma will immediately benefit Shire and is entirely
consistent with our clear strategic objective of strengthening our rare disease
portfolio. It brings us a new growth driving product which augments our already
strong growth prospects.
Shire is uniquely positioned to drive the continued success of CINRYZE for the
benefit of patients through our knowledge of the rare disease space, our
international infrastructure and our biologics manufacturing expertise.
Shire is also excited by the prospect of being able to offer two complementary
treatments, FIRAZYR for the treatment of acute HAE attacks and CINRYZE for
prophylactic treatment of patients suffering from HAE. Shire's priority will be
to ensure CINRYZE patients continue to enjoy high standards of service.
Shire has conducted a thorough and collaborative due diligence process over the
last few months and, following completion of the transaction, the integration
process will be focused on delivering value to all stakeholders. This
acquisition is expected to create a $2 billion(1) rare disease revenue base and
delivers further strong growth prospects."
Vincent J. Milano, ViroPharma's Chief Executive Officer stated:
"We are pleased to announce our merger with Shire, which like ViroPharma, is
focused on developing products for patients suffering from rare diseases.
After thoroughly evaluating our strategic options we determined that this
transaction is in the best interests of ViroPharma, our shareholders and our
patients.
By joining with Shire, ViroPharma will become part of a larger, more diverse
biopharmaceutical company and will benefit from Shire's innovation, scale and
global reach. We will have access to resources to expand product distribution,
giving us a platform to provide our crucial therapies, such as CINRYZE, to more
patients than ever before. We look forward to working with Shire's team and to
being part of an even stronger, more geographically diverse organization."
Further information on ViroPharma
ViroPharma is a leading rare disease company with CINRYZE, a high growth
product for prophylactic treatment of HAE, as well as a number of other
marketed products and a pipeline of product candidates in the rare disease
space. ViroPharma generated total worldwide net revenues of $428 million in
2012. Total worldwide net revenues are forecast by ViroPharma to be in the
range of $445 million to $465 million in 2013.
Further information on CINRYZE
In the United States, CINRYZE is indicated for routine prophylaxis against HAE
attacks in adolescent and adult patients.
HAE is a rare genetic disease characterized by recurrent sudden attacks of
swelling of the skin or the mucous membranes which can be disfiguring, painful
and potentially life-threatening in the case of laryngeal attacks. Shire
believes that of the approximately 8,000 patients in the U.S. with HAE, the
disease is only actively managed in about 3,500 patients.
CINRYZE was approved with orphan drug designation in October 2008 and has grown
rapidly since launch in 2009 to generate revenues of $321 million in the U.S.
in 2012. On October 31, 2013, ViroPharma forecasted CINRYZE net revenues in
North America in 2013 to be between $395 million and $405 million.
Shire believes there is a significant opportunity for future revenue growth, in
both the U.S. and ex-U.S. markets, as new HAE patients are identified and
treated and additional physicians gain experience with this important therapy.
Current consensus estimates(1) for global CINRYZE sales forecast strong revenue
growth in the coming years. CINRYZE has US orphan drug exclusivity which
expires in 2015 and US biologics data exclusivity until 2020.
With CINRYZE in its portfolio, Shire will be able to offer broader outreach to
HAE patients and a continuum of care alongside FIRAZYR.
Additional value from ViroPharma's other marketed products and pipeline
ViroPharma's portfolio of marketed products also includes PLENADREN®
(hydrocortisone modified release) and BUCCOLAM® (midazolam oromucosal
solution), both recently launched in major European countries. PLENADREN is a
product for adrenal insufficiency in adults. BUCCOLAM treats prolonged seizures
in infants, children and adolescents.
The acquisition also brings ViroPharma's pipeline products to Shire, including
two phase 2 products being investigated for infectious diseases: Maribavir (for
the treatment of cytomegalovirus infection in transplant patients) and VP20621
(for the prevention of recurrent Clostridium difficile infection). Also in the
ViroPharma pipeline are VP-20629 for Friedreich's Ataxia, currently in phase 1,
and an option to acquire Meritage Pharma, which is conducting phase 2 trials
with oral budesonide for the treatment of eosinophilic esophagitis. ViroPharma
has also sponsored or supported programs to examine potential new indications
for CINRYZE in Autoimmune Hemolytic Anemia, Antibody-Mediated Rejection post
renal transplantation and Neuromyelitis Optica.
Shire will review these programs as part of its regular pipeline review process
to ensure that Shire's R&D resources are appropriately deployed to those
projects that are both strategically relevant to Shire's commercial focus and
have the greatest potential for success.
Financial benefit to Shire
Shire expects the addition of CINRYZE to its Rare Disease Business Unit to
create a growing $2 billion revenue business(1) in 2014 which will represent
approximately 40% of Shire's total product sales on a pro forma basis. The
acquisition of ViroPharma is expected to enhance Shire's revenue growth profile
in both the short and long term.
Related to the acquisition, Shire estimates that it will realize approximately
$150 million of annual cost synergies across the business by 2015, over and
above the improved operating leverage already being driven by the ongoing One
Shire reorganization.
Following completion, Shire expects that the acquisition of ViroPharma will be
accretive to Shire's Non GAAP EPS immediately and in the longer term. Shire
also expects that the transaction will deliver ROIC in excess of its weighted
average cost of capital.
Financing
Shire has secured a $2.6 billion fully underwritten short term bank facility,
which, in addition to Shire's cash and cash equivalents and its existing $1.2
billion revolving credit facility, is available to finance the transaction, pay
fees and expenses related to the transaction and repay Shire's existing $1.1
billion convertible bond at its maturity in May 2014 if required. Shire plans
to refinance a portion of the short term bank facility through new debt
issuances and the use of ViroPharma's cash and short term investments.
Share Buy-back program
Following the announcement of this transaction, Shire intends to terminate its
share buyback program. Shire's Board of Directors will continue to review
Shire's capital structure on an ongoing basis.
Closing
The acquisition is structured as an all cash tender offer for all the
outstanding shares of ViroPharma common stock at a price of $50 per share
followed by a merger in which each remaining untendered share of ViroPharma
common stock would be converted into the same $50 cash per share consideration
as in the tender offer.
Closing of the transaction is subject to customary conditions, including the
tender of a majority of the outstanding ViroPharma shares and the receipt of
regulatory clearances. Pending anti-trust authority clearances, it is
anticipated that the transaction will close in the last quarter of 2013, the
first quarter of 2014 or as soon as possible thereafter. The tender offer is
not subject to a financing contingency.
Lazard and Morgan Stanley are acting as joint financial advisors to Shire.
Goldman, Sachs & Co. is acting as financial advisor to ViroPharma. Davis Polk &
Wardwell LLP is acting as legal advisor to Shire and Skadden, Arps, Slate,
Meagher & Flom LLP is acting as legal advisor to ViroPharma.
Conference Call with Shire CEO and CFO
Live conference call for investors:
Flemming Ornskov, MD, Chief Executive Officer and Graham Hetherington, Chief
Financial Officer will host the investor and analyst conference call today
(Monday 11 November 2013) at 08:30am GMT/03:30am EST.
The details of the conference call are as follows:
UK dial in: 08082370030 or 02031394830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Click here
Numbers:
Password/Conf ID: 30849732#
Live Webcast: Register here for the live webcast
Replay:
A replay of the presentation will be available for two weeks by phone and by
webcast for three months. The details of the replay are below:
Playback number: +44 (0)20 3426 2807
Playback UK toll free 0808 237 0026
number:
Password/Conf ID: 643242#
Webcast replay Click here
For further information please contact:
Investor Relations
For Shire:
Eric Rojas erojas@shire.com +1 781 482 0999
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
For ViroPharma:
Robert A. Doody Robert.doody@viropharma.com +1 610 321 6290
Media
For Shire:
Jessica Mann jmann@shire.com +44 1256 894 280
Gwen Fisher gfisher@shire.com +1 484 595 9836
For ViroPharma:
Paul Caminiti caminiti@sardverb.com +1 212 687 8080
Robin Weinberg rweinberg@sardverb.com +1 212 687 8080
Michael Henson mhenson@sardverb.com +44 20 3178 8914
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Shire's strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
Shire provides treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas.
www.shire.com
About Hereditary Angioedema
HAE is a rare genetic disease caused by low levels or a dysfunction of C1
esterase inhibitor (C1-INH). Reduced C1-INH activity can lead to elevated
plasma levels of bradykinin, which is thought to be responsible for HAE
symptoms.
HAE is characterized by recurrent sudden attacks of edema (swelling) of the
skin (hands, arms, feet, legs, thighs, face, genitals) or the mucous membranes
(gastrointestinal tract, larynx or voicebox). The swelling can be disfiguring
and painful, especially in case of abdominal attacks. Laryngeal attacks are
potentially life-threatening due to the risk of suffocation. Unlike angioedema
caused by allergic reactions, signs and symptoms such as hives and itching do
not occur in HAE. Signs and symptoms of HAE do not respond to standard
treatments for allergic angioedema such as epinephrine, corticosteroids, and
antihistamines.
About FIRAZYR
FIRAZYR is currently approved in 41 countries worldwide, including the
countries of the European Union and the United States for the treatment of
acute attacks of HAE in adults.
After injection training, patients may self-administer FIRAZYR. Most patients
respond to a single dose of FIRAZYR. If response is inadequate or if symptoms
recur, up to 2 additional doses may be administered within a 24 hour period at
intervals of at least 6 hours.
Important Safety Information
Because laryngeal attacks may be fatal, patients with laryngeal symptoms should
administer FIRAZYR and immediately seek medical attention. The most commonly
reported adverse reactions were injection site reactions, which occurred in
almost all patients (97%) in clinical trials. These most frequently included
redness and swelling. Other common adverse reactions reported in at least 1% of
patients included fever, transaminase increase, dizziness, and rash.
Full U.S. prescribing information for FIRAZYR is available at www.FIRAZYR.com.
For more information about HAE visit www.haea.org. Prescribing information may
differ between countries. Please consult your local prescribing information.
About ViroPharma
ViroPharma Incorporated is an international biopharmaceutical company committed
to developing and commercializing novel solutions for physician specialists to
address unmet medical needs of patients living with diseases that have few if
any clinical therapeutic options.
ViroPharma is developing a portfolio of therapeutics for rare and Orphan
diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV),
Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency.
ViroPharma's goal is to provide rewarding careers to employees, to create new
standards of care in the way serious diseases are treated, and to build
international partnerships with the patients, advocates, and health care
professionals it serves. ViroPharma's commercial products address diseases
including hereditary angioedema (HAE), seizures in children and adolescents,
adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full
U.S. prescribing information on ViroPharma's products, please download the
package inserts at http://www.viropharma.com/Products.aspx; the prescribing
information for other countries can be found at www.viropharma.com.
ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of
ViroPharma's web site, www.viropharma.com. ViroPharma encourages investors to
consult these sections for more information on ViroPharma and its business.
About CINRYZE (C1 esterase inhibitor [human])
Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1
esterase inhibitor product. In the U.S., Cinryze is approved by the FDA for
routine prophylaxis against angioedema attacks in adolescent and adult patients
with HAE. In the E.U., the product is approved by the EMA for the treatment
and pre-procedure prevention of angioedema attacks in adults and adolescents
with HAE, and routine prevention of angioedema attacks in adults and
adolescents with severe and recurrent attacks of HAE, who are intolerant to or
insufficiently protected by oral prevention treatments or patients who are
inadequately managed with repeated acute treatment. Cinryze is for intravenous
use only.
Severe hypersensitivity reactions to Cinryze may occur. Thrombotic events have
occurred in patients receiving Cinryze, and in patients receiving off-label
high dose C1 inhibitor therapy. Monitor patients with known risk factors for
thrombotic events. With any blood or plasma derived product, there may be a
risk of transmission of infectious agents, e.g. viruses and, theoretically, the
CJD agent. The risk has been reduced by screening donors for prior exposure to
certain virus infections and by manufacturing steps to reduce the risk of viral
transmission including pasteurization and nanofiltration.
The most common adverse reactions in clinical trials associated with Cinryze
were rash, headache, nausea, erythema, phlebitis and local reactions at the
injection site. Adverse events of sinusitis and upper respiratory infection
also were observed in clinical trials. No drug-related serious adverse events
were reported in clinical trials.
Please visit http://www.viropharma.com/products/cinryze.aspx for the full U.S.
Prescribing Information; the prescribing information for other countries can be
found at www.viropharma.com.
ADDITIONAL INFORMATION AND WHERE TO FIND IT
This announcement is for informational purposes only and does not constitute an
offer to purchase or a solicitation of an offer to sell ViroPharma common
stock. The offer to buy ViroPharma common stock will only be made pursuant to a
tender offer statement (including the offer to purchase, letter of transmittal
and other related tender offer materials). Investors and security holders are
urged to read both the tender offer statement (which will be filed by Shire
Pharmaceutical Holdings Ireland Limited (SPHIL) and a subsidiary of SPHIL with
the U.S. Securities and Exchange Commission (SEC) and the solicitation/
recommendation statement on Schedule 14d-9 with respect to the tender offer
(which will be filed by ViroPharma with the SEC) when they become available
because they will contain important information, including the terms and
conditions of the offer. Investors and security holders may obtain a free copy
of these materials (when available) and other documents filed by SPHIL and
ViroPharma with the SEC at the website maintained by the SEC at www.sec.gov.
The tender offer statement and related materials, and the solicitation/
recommendation statement, may also be obtained (when available) for free by
contacting Shire Investor Relations, at the contact information listed below.
ViroPharma also will provide a copy of these materials without charge on its
website at www.viropharma.com under the "Investors" section.
Copies of these materials and any documentation relating to the tender offer
are not being, and must not be, directly or indirectly, mailed or otherwise
forwarded, distributed or sent in, into or from any jurisdiction where to do so
would be unlawful.
Footnotes
1. Based on the most recent consensus estimates compiled by Consensus Forecast
Ltd, as of the date of this release, of combined net revenues for Elaprase,
Firazyr, Replagal and VPRIV for the year ending December 31, 2013,
available
on Shire's website (http://www.shire.com/shireplc/en/investors/forecasts)
and FactSet consensus forecasts (downloaded November 4, 2013)
for ViroPharma and for the year ending December 31, 2014 for Shire.
SHIRE FORWARD - LOOKING STATEMENTS
Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that:
Shire's products may not be a commercial success;
revenues from ADDERALL XR are subject to generic erosion;
the failure to obtain and maintain reimbursement, or an adequate level of
reimbursement, by third-party payors in a timely manner for Shire's products
may impact future revenues and earnings;
Shire relies on a single source for manufacture of certain of its products
and a disruption to the supply chain for those products may result in Shire
being unable to continue marketing or developing a product or may result in
Shire being unable to do so on a commercially viable basis;
Shire uses third party manufacturers to manufacture many of its products
and
is reliant upon third party contractors for certain goods and services, and any
inability of these third party manufacturers to manufacture products, or any
failure of these third party contractors to provide these goods and services,
in each case in accordance with its respective contractual obligations, could
adversely affect Shire's ability to manage its manufacturing processes or to
operate its business;
the development, approval and manufacturing of Shire's products is subject
to
extensive oversight by various regulatory agencies and regulatory approvals or
interventions associated with changes to manufacturing sites, ingredients or
manufacturing processes could lead to significant delays, increase in operating
costs, lost product sales, an interruption of research activities or the delay
of new product launches;
the actions of certain customers could affect Shire 's ability to sell or
market products profitably and fluctuations in buying or distribution patterns
by such customers could adversely impact Shire's revenues, financial conditions
or results of operations;
investigations or enforcement action by regulatory authorities or law
enforcement agencies relating to Shire's activities in the highly regulated
markets in which it operates may result in the distraction of senior
management, significant legal costs and the payment of substantial compensation
or fines;
Shire's proposed acquisition of ViroPharma may not be consummated due to
the
occurrence of an event, change or other circumstances that gives rise to the
termination of the merger agreement;
a governmental or regulatory approval required for the proposed acquisition
of ViroPharma may not obtained, or may be obtained subject to conditions that
are not anticipated, or another condition to the closing of the proposed
acquisition may not be satisfied;
ViroPharma may be unable to retain and hire key personnel and/or maintain
its
relationships with customers, suppliers and other business partners pending the
consummation of the proposed acquisition by Shire, or ViroPharma's business may
be disrupted by the proposed acquisition, including increased costs and
diversion of management time and resources;
difficulties in integrating ViroPharma into Shire may lead to the combined
company not being able to realize the expected operating efficiencies, cost
savings, revenue enhancements, synergies or other benefits at the time
anticipated or at all;
and other risks and uncertainties detailed from time to time in Shire's or
ViroPharma's filings with the U.S. Securities and Exchange Commission,
including their respective most recent Annual Reports on Form 10-K.
VIROPHARMA FORWARD - LOOKING STATEMENTS
Statements contained or incorporated by reference in this document contain
information that includes or is based on "forward-looking statements". These
statements include statements regarding planned completion of the offer and the
merger. We have tried, whenever possible, to identify such statements by words
such as "believes," "expects," "anticipates," "intends," "estimates," "plan,"
"projected," "forecast," "will," "may" or similar expressions. Because these
statements reflect our current views concerning future events and are based on
a number of assumptions that could ultimately prove inaccurate, these
forward-looking statements are subject to risks and uncertainties including,
but not limited to: all elements of our financial guidance for 2013, our
ability to continue to successfully commercialize our products in the United
States and Europe, the timing and results of anticipated events in our clinical
development programs, and our ability to identify and execute upon business
development opportunities.
Our actual results may vary depending on a variety of factors, including:
* our ability to continue to identify and retain prophylaxis Cinryze patients
in the United States and Europe at the rate we anticipate, the total number
of potential prophylaxis Cinryze patients in the United States and Europe
and our market share of HAE patients in the United States and Europe;
* the size of the market, future growth potential and market share for
Buccolam and Plenadren in Europe;
* the availability of sufficient third party payer reimbursement for each of
our products in the United States and Europe;
* fluctuations in wholesaler and SP order patterns and inventory levels;
* competition from the approval of products which are currently marketed for
other indications by other companies or new pharmaceuticals and
technological advances to treat the conditions addressed by
Cinryze, Buccolam and Plenadren;
* changes in prescribing or procedural practices of physicians, including
off-label prescribing of products competitive with Cinryze, Buccolam and
Plenadren;
* manufacturing, supply or distribution interruptions, including but not
limited to our ability to acquire adequate supplies of Cinryze and our
other products in order to meet demand for each product;
* our ability to receive regulatory approval for the use of Cinryze for
additional indications and routes of administration and in additional
territories in the timeframes we anticipate or at all;
* the impact of healthcare reform legislation in the United States;
* actions by the FDA and EMA or other government regulatory agencies;
* the timing and results of anticipated events in our clinical development
programs including studies with Cinryze subcutaneous formulations, Cinryze
for antibody mediated rejection, and maribavir for treatment of CMV
infections in transplant recipients; and
* whether we pursue regulatory approval of Plenadren in the United States.
Biologics such as Cinryze require processing steps that are more difficult than
those required for most chemical pharmaceuticals, and as a result, Sanquin, our
manufacturer of Cinryze has received observations on Form 483 and a warning
letter which require us to continue to meet commitments made to the FDA related
to various manufacturing issues. In the event Sanquin fails to meet these
commitments, the FDA may take actions that limit our ability to manufacture
Cinryze. In the event Sanquin is not able to manufacture the anticipated volume
of product at the industrial scale as a result of either FDA requirements,
batch failures, variability in batch yields, required maintenance or other
causes, we may not be able to satisfy patient demand or build safety stock. Our
inability to obtain adequate product supplies to satisfy our patient demand may
create opportunities for our competitors and we will suffer a loss of potential
future revenues.
Forward looking statements related to the transaction include: the timing of
the filings and approvals relating to the transaction and the expected timing
of the completion of the transaction; uncertainties as to the percentage of the
ViroPharma's stockholders tendering their shares in the offer; the possibility
that competing offers will be made; the possibility that various closing
conditions for the transaction may not be satisfied or waived, including that a
governmental entity may prohibit, delay or refuse to grant approval for the
consummation of the transaction or may approve the transaction with certain
burdensome conditions that may result in a termination of the Merger Agreement;
the effects of disruption caused by the transaction making it more difficult to
maintain relationships with employees, collaborators, vendors and other
business partners; the risk that stockholder litigation in connection with the
transaction may result in significant costs of defense, indemnification and
liability; and other risks and uncertainties discussed in the ViroPharma's
filings with the SEC, including the "Risk Factors" sections of the ViroPharma's
most recent annual report on Form 10-K and subsequent quarterly reports on Form
10-Q, as well as the tender offer documents to be filed by SPHIL and a
subsidiary of SPHIL, and the Solicitation/Recommendation Statement to be filed
by ViroPharma. These risks, uncertainties and other factors, individually or
in the aggregate, could cause actual results and events to differ materially
from those referred to in the forward-looking statements. All forward-looking
statements are based on information currently available to ViroPharma, and
ViroPharma assumes no obligation to update any such forward-looking
statements.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com
END
-0- Nov/11/2013 07:00 GMT